

COMPUMEDICS LIMITED

(ACN 006 854 897)

ASX Preliminary final report – 30 June 2004

Lodged with the ASX under Listing Rule 4.3A

Contents

Results for Announcement to the Market <i>(Appendix 4E item 2)</i>	1
Preliminary consolidated statement of financial performance <i>(Appendix 4E item 3)</i>	2
Preliminary consolidated statement of financial position <i>(Appendix 4E item 4)</i>	3
Preliminary consolidated statement of cash flows <i>(Appendix 4E item 5)</i>	4
Other Appendix 4E Information <i>(Appendix 4E items 6 to 17)</i>	5

Compumedics Limited
Year ended 30 June 2004
(Previous corresponding period:
Year ended 30 June 2003)

Results for Announcement to the Market

				\$'000
Revenue from ordinary activities <i>(Appendix 4E item 2.1)</i>	up/down	6%	to	33,963
Earnings before interest, tax, depreciation and amortisation	up/down	55%	to	2,944
Profit/(loss) from ordinary activities after tax attributable to members <i>(Appendix 4E item 2.2)</i>	up/down	N/A	to	2,397
Net profit/(loss) for the period attributable to members <i>(Appendix 4E item 2.3)</i>	up/down	N/A	to	2,397

Dividends/distributions <i>(Appendix 4E item 2.4)</i>	Amount per security	Franked amount per security
Final dividend	N/A	N/A
Interim dividend	N/A	N/A

Record date for determining entitlements to the dividend
(Appendix 4E item 2.5)

Not applicable

Explanation of Revenue *(Appendix 4E item 2.6)*

Revenues increased by 6% from \$32.1m to \$34.0m over the previous corresponding period. The US business in US dollars grew by 35% of the previous year to USD12.8m.

Explanation of Earnings before interest, tax, depreciation and amortisation
(Appendix 4E item 2.6)

EBITDA increased by 55% from \$1.9m to \$2.9m for the financial year ending 30 June 2004. This improvement reflects strong gains in the operational efficiency of the business during the year.

Explanation of Profit/(loss) from ordinary activities after tax *(Appendix 4E item 2.6)*

The business returned to profits after tax for the year at a record \$2.4m compared to last year's result of a loss of \$18.6m. Last year's results were impacted by the decision to write off all intangible assets at that time.

Explanation of Dividends *(Appendix 4E item 2.6)*

The Directors are currently reviewing the dividend policy of the company and will inform the market when a decision has been made.

Compumedics Limited
Preliminary consolidated statement of financial performance
For the year ended 30 June 2004

		2004	2003
	Notes	\$'000	\$'000
Revenue from sale of goods and services		33,963	32,056
Cost of sales		(14,580)	(14,170)
Gross profit		19,383	17,886
Other revenues from operating activities		376	382
Administration		(3,487)	(4,230)
Sales & Marketing		(6,842)	(6,267)
Research & Development		(6,500)	(6,708)
Service	1	-	(1,966)
Logistics	1	-	(648)
Borrowing costs		(268)	(187)
Accelerated Amortisation Charge		-	(17,858)
Net foreign exchange gain/(loss)		(254)	631
Profit / (Loss) from ordinary activities before income tax (expense) / benefit		2,409	(18,965)
Income tax benefit / (expense)		(12)	408
Profit / (Loss) from ordinary activities after income tax (expense) / benefit		2,397	(18,557)
Net profit / (loss) attributable to members of Compumedics Limited		2,397	(18,557)
Total changes in equity other than those resulting from transactions with owners as owners		2,397	(18,557)
Earnings per share (cents):			
Basic		1.7	(13.3)
Diluted		1.7	(13.3)
Basic earnings per share based on earnings before interest, tax, depreciation and amortisation		2.1	1.4
Diluted earnings per share based on earnings before interest, tax, depreciation and amortisation.		2.1	1.4

Notes

1. In the prior year service and logistics expenses were disclosed separately. In the current year these items now form part of cost of goods sold.

Compumedics Limited
Preliminary consolidated statement of financial position
As at 30 June 2004

	2004	2003
	\$'000	\$'000
CURRENT ASSETS		
Cash assets	6,352	5,366
Receivables	10,239	8,624
Inventories	6,481	8,416
Other	69	180
TOTAL CURRENT ASSETS	23,141	22,586
NON-CURRENT ASSETS		
Property, plant and equipment	1,368	1,176
NON-CURRENT ASSETS	1,368	1,176
TOTAL ASSETS	24,509	23,762
CURRENT LIABILITIES		
Payables	4,614	5,120
Interest bearing liabilities	1,884	4,729
Current tax liabilities	55	52
Provisions	346	304
Other	1,330	1,217
TOTAL CURRENT LIABILITIES	8,229	11,422
NON CURRENT LIABILITIES		
Interest bearing liabilities	2,122	508
Provisions	198	157
Other	15	-
TOTAL NON-CURRENT LIABILITIES	2,335	665
TOTAL LIABILITIES	10,564	12,087
NET ASSETS	13,945	11,675
EQUITY		
Contributed equity	29,020	29,147
Retained profits	(15,075)	(17,472)
TOTAL EQUITY	13,945	11,675

Compumedics Limited
Preliminary consolidated statement of cash flows
For the year ended 30 June 2004

	Note	2004 \$'000	2003 \$'000
CASH FLOW FROM OPERATING ACTIVITIES			
Receipts from customers (inclusive of goods and services tax)		32,625	31,782
Payments for R&D activities (inclusive of goods and services tax)	1	(6,500)	-
Other payments to suppliers and employees (inclusive of goods and services tax)		(23,603)	(29,022)
		(30,103)	(29,022)
Interest and other items of a similar nature received		196	234
Other revenue		181	148
Interest and other costs of finance paid		(268)	(187)
Income taxes paid		15	-
Net cash inflow (outflow) from operating activities		2,646	2,955
CASH FLOWS FROM INVESTING ACTIVITIES			
Payment for purchase of controlled entity, net of cash acquired		(2,293)	(734)
Payments for property, plant and equipment		(669)	(770)
Payments for goodwill acquired		-	(19)
Payments for intellectual property costs	1	-	(3,948)
Receipts of grants for intellectual property		-	59
Proceeds from sale of Property, plant and equipment		6	-
Net cash inflow (outflow) from investing activities		(2,956)	(5,412)
CASH FLOWS FROM FINANCIAL ACTIVITIES			
Proceeds from borrowings		3,847	-
Repayments of finance leases		(43)	(132)
Payment of GST on IPO		(127)	-
Repayment of borrowings		(2,381)	(578)
Net cash inflow (outflow) from financing activities		1,296	(710)
NET INCREASE (DECREASE) IN CASH HELD		986	(3,167)
Cash at the beginning of the year		5,366	8,533
CASH AT THE END OF THE FINANCIAL YEAR		6,352	5,366

Note:

1. Payments for Australian research and development activities, previously recorded as payments for intellectual property, have been included in cash flow from operating activities this year.

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Material factors affecting the revenues and expenses of the economic entity for the current period

The material factors effecting revenue for the period was the movement in the AUD/USD exchange rate. Had the AUD not appreciated against the USD by 21% in the year ended 30 June 2004, the reported revenue number would have been \$39.4m. The major factor in the underlying growth in revenues ignoring the exchange rate was the growth in the US business revenues by 35% in US dollars from USD9.5m to USD12.8m.

The net impact on the EBIT line related to the 31% appreciation of the AUD against the USD was \$(1.1) m. That is to say the business would have reported EBIT of \$3.6m rather than \$2.5m.

Material factors affecting the assets, liabilities and equity of the economic entity for the current period

The major impact effecting assets and liabilities for the period was the renegotiation of debt in December 2003 related to the acquisition of the Neuroscan business in April 2002. In December 2003 the remaining USD debt was converted to Australian dollars and the payment schedule increased to be repayable over a three-year period.

Debts of AUD 1.7m and 2.3m were repaid to the National Australia Bank and to the Marmon group respectively. New borrowings with the ANZ were instigated and the details of those new borrowings at the 30th June 2004 are:

Principal to be repaid	\$3.35m
Quarterly repayment amounts	\$0.35m
Number of quarterly repayments remaining	9.5

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Material factors affecting the cash flows of the economic entity for the current period

The net cash balance of the entity improved to \$6.3m for the period end compared to \$5.4m for the previous period. This improvement was largely driven by operational efficiencies gained during the year, which led the business back to profits and greater control of working capital as represented by the reduction in inventories for the period from \$8.4m at June 30, 2003 to \$6.5m at June 30, 2004.

Changes in accounting policies

There were no changes in accounting policies during the year.

Fundamental errors

There were no fundamental errors noted in the accounts

Extraordinary items

There were no extra ordinary items noted in the accounts

Reconciliation of income tax expense

	2004 \$'000	2003 \$'000
The income tax expenses for the financial year differs from the amount calculated on the profit.		
The differences are reconciled as follows:		
Profit from ordinary activities before income tax expense / (benefit)	2,409	(18,965)
Income tax calculated @ 30%	723	(5,690)
Tax effect of permanent differences		
25% Non-grant R&D loading / allowance	(324)	(248)
Other permanent differences	(60)	(111)
Non-deductible amortisation	-	-
Non deductible intellectual property write down	-	2,614
Timing differences not brought to account	521	865
Utilisation of prior year tax losses	(830)	-
Current tax losses not brought to account	-	1,646
Write off tax losses previously brought to account	-	671
	30	(253)
Under (over) provision in previous year	(18)	(155)
Aggregate income tax expense / (benefit)	12	(408)

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Reconciliation of profit from ordinary activities after income tax to net cash flow from operating activities

	2004 \$'000	2003 \$'000
Profit/Loss from ordinary activities	2,397	(18,557)
Depreciation & amortisation	471	20,914
Exchange gain on Loans payable	(383)	-
Doubtful debts	(235)	(69)
Change in operating assets and liabilities, net of effects from purchase of controlled entity		
Decrease (Increase) in trade and other debtors	(1,380)	(269)
Decrease (Increase) in inventories	1,935	104
Decrease (Increase) in income tax receivables	78	-
Decrease (Increase) in other operating assets	33	(191)
(Decrease) Increase in trade creditors	(480)	1,530
(Decrease) Increase in other operating liabilities	125	(378)
(Decrease) Increase in provision for income taxes payable	3	(178)
(Decrease) Increase in provision for deferred income tax	-	(254)
(Decrease) Increase in other provisions	82	303
Net cash inflow / (outflow) from operating activities	2,646	2,955

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Segment reporting – Primary
For the year ended 30 June 2004

					\$'000	
	Sleep	Neuroscan	Neuroscience	NMS*	Unallocated/ Elimination	Group
Sales to external customers	18,215	10,917	1,975	2,856		33,963
Intersegment sales						-
Total sales revenue	18,215	10,917	1,975	2,856	-	33,963
Other revenue	96	58	11	15		181
Total segment revenue	18,313	10,975	1,985	2,871	-	34,144
SEGMENT RESULT	1,945	1,708	(881)	181	(472)	2,481
Interest expense/ (income)						72
Tax expense/(credit)						12
PAT						2,397
Segment assets	8,322	5,092	1,234	1,720		16,368
Unallocated assets						8,141
Tax assets						-
Total assets						24,509
Segment liabilities	2,932	5,764	318	460		9,474
Unallocated liabilities						1,035
Tax liabilities						55
Total liabilities						10,564
Net assets						13,945
Acquisition of PPE	-	-	-	-	652	652
Acquisition of intangibles and other non-current segment Assets	-	-	-	-	-	-
Depreciation and amortisation	-	-	-	-	(472)	(472)
Other non-cash expenses	-	-	-	-	-	-

* NMS = Neuro Medical Supplies

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Segment reporting – Primary
For the year ended 30 June 2003

						\$'000
	Sleep	Neuroscan	Neuroscience	NMS*	Unallocated/ Elimination	Group
Sales to external customers	17,677	9,649	2,139	2,591		32,056
Intersegment sales						-
Total sales revenue	17,677	9,649	2,139	2,591		32,056
Other revenue	81	44	11	12		148
Total segment revenue	17,758	9,693	2,150	2,603	-	32,204
SEGMENT RESULT	(6,179)	(7,170)	(5,778)	624	(509)	(19,012)
Interest expense/ (income)						(47)
Tax expense/(credit)						(408)
PAT						(18,557)
Segment assets	10,259	3,560	858	2,363		17,040
Unallocated assets						6,722
Tax assets						-
Total assets						23,762
Segment liabilities	4,020	6,336	305	370		11,032
Unallocated liabilities						1,055
Tax liabilities						-
Total liabilities						12,087
Net assets						11,675
Acquisition of PPE	-	-	-	-	771	771
Acquisition of intangibles and other non-current segment Assets	2,763	1,126	-	-	-	3,889
Depreciation and amortisation	9,747	4,199	6,269	190	509	20,914
Other non-cash expenses	-	-	-	-	-	NIL

* NMS = Neuro Medical Supplies

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Segment reporting – Secondary
For the year ended 30 June 2004

				\$'000
	USA	ROW	Unallocated/ Elimination	Group
Sales to external customers	18,020	15,943		33,963
Intersegment sales	1,348	5,037	(6,385)	-
Total sales revenue	19,368	20,980	(6,385)	33,963
Other revenue	1	180	-	181
Total segment revenue	19,369	21,160	(6,385)	34,144
Segment Assets	3,484	21,081	(56)	24,509
Unallocated assets				-
Tax assets				-
Total assets				24,509
Acquisition of PPE	235	417	-	652
Acquisition of intangibles and other non-current segment assets				

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Segment reporting – Secondary
For the year ended 30 June 2003

	USA	ROW	Unallocated/ Elimination	\$'000 Group
Sales to external customers	16,190	15,866		32,056
Intersegment sales	1,632	4,077	(5,709)	-
Total sales revenue	17,822	19,943	(5,709)	32,056
Other revenue	-	148	-	148
Total segment revenue	17,822	20,091	(5,709)	32,204
Segment Assets	8,262	20,624	(5,124)	23,762
Unallocated assets				-
Tax assets				-
Total assets				23,762
Acquisition of PPE	112	659	-	771
Acquisition of intangibles and other non-current segment assets	-	3,889	-	3,889

Compumedics Limited
Notes to the preliminary consolidated financial statements
For the year ended 30 June 2004

Discontinuing operations

None to report in the period

Events occurring after reporting date

The Company is not aware at the date of release of this information of any event that has occurred since reporting date that would impact the financial performance of or position of Compumedics Limited as reported.

Compumedics Limited

Supplementary Appendix 4E information

Additional dividend/distribution information ² (Appendix 4E item 6)

Details of dividends/distributions declared or paid during or subsequent to the year ended 30 June 2004 are as follows: **NOT APPLICABLE**

Record date	Payment date	Type	Amount per security	Total dividend	Franked amount per security	Foreign sourced dividend amount per security
N/A	N/A	N/A	N/A	N/A	N/A	N/A

Dividend/distribution reinvestment plans (Appendix 4E item 7)

NOT APPLICABLE

Retained Earnings (Appendix 4E item 8)

	2004 \$'000	2003 \$'000
Retained earnings at the beginning of the financial year	(17,472)	1,084
Net profit attributable to members of Compumedics Limited	2,397	(18,556)
Dividends provided for or paid	-	-
Retained profits at the end of the financial year	<u>(15,075)</u>	<u>(17,472)</u>

NTA Backing (Appendix 4E item 9)

	2004	2003
Net tangible asset backing per ordinary share	9.9 cents	8.3 cents

Controlled entities acquired or disposed of (Appendix 4E item 10)

Acquired			
Date control gained	Date	Date	Date
Contribution to profit from ordinary activities after tax in current period, where material	N/A	N/A	N/A
Profit from ordinary activities after tax during the whole of the previous corresponding period, where material	N/A	N/A	N/A

Disposed of			
Date control lost	Date	Date	Date
Contribution to profit from ordinary activities after tax in current period, where material	N/A	N/A	N/A
Profit from ordinary activities after tax during the whole of the previous corresponding period, where material	N/A	N/A	N/A

Compumedics Limited

Supplementary Appendix 4E information

Associates and Joint Venture entities *(Appendix 4E item 11)*

Name	Ownership interest		Aggregate share of profits/(losses), where material		Contribution to net profit, where material	
	2003 %	2002 %	2003 \$	2002 \$	2003 \$	2002 \$
	N/A	N/A	N/A	N/A #	N/A	N/A

Other significant information *(Appendix 4E item 12)*

Commentary as already provided.

Commentary on results *(Appendix 4E item 14)*

Earnings per share

Earnings per share improved from (13.3) cents to 1.7 cents as a result of restoration of profitability. The profitability resulted from growth and operational gains during the year.

Returns to shareholders

As per earnings per share commentary.

Significant features of operating performance

Comments already noted.

Results of segments

Primary Segments:

All segments of the business, except for the Neuroscience division, grew during the year ended 30 June 2004, albeit at lower rates than expected, due to the strong Australian dollar and the focus on profitability.

As a result of the focus on profitability, all segments of the business achieved profits in the year, except for Neuroscience. Neuroscience is in an expansion phase of its business and as a consequence is being invested in to ensure its growth and profitability over the years ahead.

Both the Sleep and Neuroscan businesses generated profits during the year. The focus will be to continue to grow the revenues and profits of these divisions.

Compumedics Limited

Supplementary Appendix 4E information

Trends in performance

The Company expects revenues to continue to grow.

Margins and earnings should continue to improve with the growth in the company. The business has in place the structures for each of its markets and the focus will be on delivering earnings and cash from these activities

Other factors that affected results in the period or which are likely to affect results in the future

All material matters have been discussed.

Foreign Accounting standards *(Appendix 4E item 13)*

Not applicable

Audit *(Appendix 4E items 15 - 17)*

This report is based on accounts that are in the process of being audited.